TGTX
TG Therapeutics Inc
56.50$
+1.1%
vs. previous close
Closing price · As of: Sep 17, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2.1% | 18.1% | 8.7% | 11.3% | 11.1% | 14.2% | 12.9% | 13.4% | 17.4% | 19.8% | 16.4% | 17.1% | 17.6% | |
| 97.9% | 81.9% | 91.3% | 88.7% | 88.9% | 85.8% | 87.1% | 86.6% | 82.6% | 80.2% | 83.6% | 82.9% | 82.4% | |
| 8.9% | 39.7% | 51.6% | 23.9% | 24.0% | 22.1% | 38.4% | 22.5% | 25.3% | 21.4% | 23.6% | 39.7% | 28.2% | |
| 19.8% | 77.3% | 54.5% | 52.8% | 50.0% | 36.0% | 41.6% | 39.4% | 39.2% | 32.6% | 43.0% | 34.2% | 37.1% | |
| 28.7% | 110.3% | 105.9% | 76.7% | 74.0% | 58.1% | 80.0% | 61.9% | 64.4% | 54.0% | 66.7% | 73.8% | 65.3% | |
| 69.2% | -28.4% | -14.6% | 12.0% | 14.8% | 27.7% | 7.1% | 24.7% | 18.2% | 26.2% | 17.0% | 9.0% | 17.1% | |
| 2.2% | 5.5% | 3.6% | 5.4% | 12.9% | 6.5% | 5.6% | 4.8% | 4.2% | 3.4% | 3.7% | 6.9% | 4.7% | |
| 68.7% | -31.9% | -16.8% | 8.9% | 5.1% | 23.5% | 4.5% | 21.9% | 16.0% | 23.4% | 9.9% | 4.3% | 12.7% | |
| -0.1% | 0.9% | 0.0% | -0.4% | 0.5% | 2.0% | 0.3% | 1.9% | -225.7% | 11.5% | 0.3% | 1.0% | -42.5% | |
| 68.7% | -32.8% | -16.9% | 9.4% | 4.6% | 21.6% | 4.2% | 20.0% | 241.7% | 12.0% | 9.7% | 3.2% | 55.2% | |
| 71.0% | -26.2% | -13.1% | 14.4% | 18.1% | 30.1% | 10.2% | 26.7% | 20.2% | 26.8% | 13.7% | 9.0% | 16.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.